Financial Data and Key Metrics Changes - In Q4 2025, net product revenues were $22.3 million, up from $16.4 million in Q4 2024, indicating a strong performance [21] - For the full year 2025, net product revenues reached $73.6 million, compared to $69.3 million in 2024, showing stability in revenue generation [21] - Total operating expenses for Q4 2025 were $41 million, while for the full year, they were $202.9 million, reflecting a disciplined approach to cost management [21][22] - The net loss for Q4 2025 was $6.4 million, significantly reduced from a loss of $30.7 million in Q4 2024 [22][23] Business Line Data and Key Metrics Changes - The focus on ZYNLONTA has led to a refined go-to-market model, maintaining its position in the third-line plus DLBCL setting despite increased competition from bispecific therapies [5][6] - The company anticipates significant growth opportunities in the second-line plus DLBCL setting with LOTIS-5, expecting to share top-line data in Q2 2026 [8][10] Market Data and Key Metrics Changes - The treatment landscape for DLBCL is evolving, with a current 60/40 split between complex therapies and broadly accessible therapies, impacting market dynamics [15] - The company estimates that achieving a 10% market share in the second-line setting could translate to an additional $200 million to $300 million in revenue [20] Company Strategy and Development Direction - The strategic plan focuses on optimizing lifecycle management for ZYNLONTA, including advancing LOTIS-5 and initiating LOTIS-7 [5][6] - The company aims to establish ZYNLONTA as a backbone therapy in DLBCL, targeting peak annual revenues of $600 million to $1 billion with regulatory approvals and compendia listings [7][11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's path forward, highlighting a strengthened balance sheet and a cash runway expected to last into 2028 [10][24] - The anticipated data catalysts in 2026 are expected to drive significant long-term growth, particularly with the LOTIS-5 and LOTIS-7 trials [25][26] Other Important Information - The company has successfully reduced its operating cost structure by approximately 50%, enhancing its strategic flexibility [5][6] - The amendment to the royalty purchase agreement with HealthCare Royalty reflects the company's confidence in ZYNLONTA's long-term value [9][10] Q&A Session Summary Question: How are PFS events tracking for LOTIS-5? - Management is confident in the Q2 timing for the top-line readout and will share primary and secondary endpoints at that time [29][30] Question: Is the $200-$300 million opportunity for LOTIS-5 conservative? - Management believes the profile seen in the safety run-in supports a meaningful role in the second-line plus DLBCL market, with potential for higher peak sales depending on clinical outcomes [34][35] Question: What is the expected R&D spend moving forward? - R&D expenses are expected to decrease in 2026 and 2027, assuming the current number of trials remains stable [42][44] Question: How will capital allocation priorities be managed? - The company is focused on driving ZYNLONTA growth and has allocated capital for ongoing trials and pre-launch activities [48][50] Question: What is the current commercial run rate for ZYNLONTA? - The company has maintained its market share despite increased competition, with expectations for significant sales growth following LOTIS-5 approval [58][59]

Financial Data and Key Metrics Changes - Revenue grew 6.1% year-over-year to $2.2 billion, driven by 5.5% organic growth and a modest contribution from an acquisition in Ireland [14] - Net income for the quarter was $38.8 million or $0.64 per diluted share, compared to $43.6 million or $0.69 per share in the prior year [15] - Adjusted EBITDA was $117.8 million, compared to $120.6 million in the prior year [16] Business Line Data and Key Metrics Changes - B&I segment revenue was $1.1 billion, up 4% year-over-year, with operating profit of $79.7 million and a margin of 7.5% [16] - Aviation revenue grew 10% to $297.7 million, with an operating profit of $12.6 million and a margin of 4.2% [17] - M&D generated $422.3 million in revenue, a 7% increase year-over-year, with an operating profit of $36.3 million and a margin of 8.6% [19] - Education revenue rose 2% to $228.7 million, with operating profit increasing 54% to $21.6 million and margin expanding to 9.4% [20] - Technical Solutions revenue was $229.7 million, up 14% year-over-year, but faced margin decline to 3.7% due to project timing and service mix [21] Market Data and Key Metrics Changes - Demand remains generally healthy across end markets, with improving transaction volumes in prime office spaces [4] - The aviation segment is supported by resilient TSA checkpoint volumes and ongoing airport infrastructure investments [5] - The semiconductor manufacturing sector is experiencing accelerated public and private investment, with a forecast of over $1.5 trillion in fabrication facility investment through 2030 [7] Company Strategy and Development Direction - The company is focused on strengthening its semiconductor capabilities through the WGNSTAR acquisition and enhancing its service offerings in energy resiliency and mission-critical operations [7][27] - The full-year outlook remains unchanged, with expectations of organic growth of 3%-4% and total growth of 4%-5% including acquisitions [24][25] - The company is investing in AI-driven technologies to enhance operational efficiency and service delivery [11] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism regarding the operating environment, acknowledging macroeconomic uncertainties while maintaining confidence in demand across markets [12][27] - The company expects a stronger performance in the second half of the fiscal year, particularly in Technical Solutions, as project timing normalizes [22][32] Other Important Information - The company ended the quarter with total indebtedness of $1.7 billion and available liquidity of $608 million [22] - Free cash flow for the quarter was $48.9 million, representing significant improvement over the prior year [23] Q&A Session Summary Question: Impact of project timing on margins - Management confirmed that project timing issues were primarily due to weather disruptions, with confidence that delays will be resolved in upcoming quarters [30] Question: Expected trajectory for margins throughout the year - Management indicated that historically, two-thirds of operating profit in the ATS business occurs in the second half of the year, suggesting a similar pattern for the current fiscal year [32] Question: Customer behavior in B&I segment - Management noted stable customer behavior with no significant requests for pricing concessions, although a large contract exit in the UK is expected to impact revenue [37] Question: Balancing capital deployment and deleveraging - Management stated that free cash flow will be used to reduce leverage back towards the target range below 3x following the WGNSTAR acquisition [42] Question: Education segment margins sustainability - Management expressed optimism about the education segment's margin profile, although some pressure is expected in the next quarter due to weather-related school closures [75] Question: Update on restructuring process - Management confirmed that the $35 million restructuring project was completed last year, with benefits expected to roll through the first half of the current year [84]

Financial Data and Key Metrics Changes - The company reported a full-year EBITDA of $111 million, an 11% increase over 2024, with an EBITDA margin of 37% [19] - The fourth quarter EBITDA margin reached a record 42%, the highest in the company's history [5] - The company is projecting 2026 EBITDA guidance of $112 million to $118 million, with a midpoint of $115 million representing low double-digit growth over 2025 [6][19] Business Line Data and Key Metrics Changes - The interactive business grew revenue and EBITDA by 53% and 60% respectively in the fourth quarter [4] - More than 80% of the company's revenue is recurring, indicating a stable revenue stream [9] - The digital business accounted for 51% of EBITDA in 2025 and is expected to grow to over 60% by 2027 [19][20] Market Data and Key Metrics Changes - The company is experiencing strong growth in the North American market, particularly with the launch of its Virtuals business with BetMGM [10] - iGaming is more than three times the size of sports betting in states where they compete head-to-head, presenting a significant opportunity for the company [12] Company Strategy and Development Direction - The company is focusing on an asset-light business model, which is positively impacting free cash flow and is expected to continue through 2026 [7][9] - The company plans to combine its gaming and remaining leisure businesses into one reporting entity called Retail Solutions, simplifying its story and reflecting its current management structure [20] - The company is targeting to de-leverage to 2.5-3 times net leverage by year-end 2026 [7] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ongoing momentum of the interactive business, with no signs of slowing down [11][35] - The company is optimistic about the potential for additional states to legalize iGaming, which could significantly enhance growth [12] - Management noted that the impact of tax changes in the UK is manageable and that operators are adjusting their strategies accordingly [24][25] Other Important Information - The company launched a cloud-based lottery platform, which is expected to generate significant revenue in the coming years, particularly outside the U.S. [61][63] - The company is focused on maintaining strong relationships with key customers, which is crucial for contract renewals and product innovation [9] Q&A Session Summary Question: Impact of UK tax changes on guidance - Management indicated that UK operators are adjusting their RTP and bonusing structures to mitigate the impact of tax changes, and they feel comfortable with the expected outcomes [24][25] Question: Capital allocation strategy amid changing valuations - Management acknowledged the potential for share repurchase but emphasized a focus on deleveraging, while also considering stock valuations in their asset allocation [29][30] Question: Expectations for iGaming market share growth - Management noted that the momentum in the interactive business is expected to continue, with strong performance from major customers [36][38] Question: Retail strategies in response to tax changes - Management stated that operators are looking to balance online and retail business to mitigate tax impacts, with some lower-performing shops being taken over by independent operators [42][45] Question: Virtual Sports revenue expectations - Management acknowledged a mixed performance in Virtual Sports but expressed confidence in margin sustainability and ongoing revenue growth initiatives [46][49]

Financial Data and Key Metrics Changes - Revenue for the full year 2025 reached approximately $120 million, reflecting a 10% year-over-year growth driven by improvements in average selling price and volumes [51][58] - Adjusted EBITDA for 2025 was $13.2 million, representing a 26% improvement compared to 2024, despite the impact of GAC startup costs [51][52] - Q4 2025 revenue totaled $29.4 million, up around 8% year-over-year, with a gross margin of 13.6%, significantly impacted by GAC ramp-up costs [54][55] Business Line Data and Key Metrics Changes - The PAC business delivered exceptional performance in 2025, with revenues reaching approximately $120 million, up 10% year-over-year, and adjusted EBITDA of $13 million [38][51] - The company is pausing GAC production to conduct a comprehensive engineering and production process optimization review, with no GAC production expected in 2026 [9][25] Market Data and Key Metrics Changes - The GAC market fundamentals remain strong, with persistent supply shortages against steady annual growth from existing demand drivers [27][28] - The company anticipates that the PAC business will continue to be cash generative in fiscal year 2026 and beyond, with strong visibility into future demand [56][58] Company Strategy and Development Direction - The company is focused on optimizing its GAC production process and has made strategic changes to its leadership team to enhance operational efficiency [32][36] - The shift towards specialty products and engineered materials is expected to improve the business profile and command premium pricing [43][49] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term demand for GAC, citing a significant demand-supply imbalance that is expected to persist [70][108] - The company is committed to making disciplined capital allocation decisions and is focused on rebuilding investor confidence through consistent execution [62][64] Other Important Information - The company is taking a $45 million write-down on its Corbin assets as part of its decision to switch GAC feedstock to purchased bituminous coal [29][30] - The company ended the year with total cash of $15 million and total debt of $28.5 million, reflecting an increase due to higher utilization of its credit facility [57] Q&A Session Summary Question: Is there anything preventing the company from pursuing GAC? - Management confirmed there are no barriers to pursuing GAC, emphasizing strong market fundamentals and expected demand [70][71] Question: Any commentary on regulatory undercurrents affecting PAC? - Management stated there is no regulatory uncertainty affecting the PAC business, with existing regulations remaining intact [72] Question: Guidance and free cash flow expectations? - Management indicated that the PAC business is expected to generate free cash flow, with maintenance CapEx anticipated to be lower in the following year [73] Question: Capacity to supply the market if demand increases? - Management confirmed there is capacity to expand PAC production to meet increased demand without cannibalizing GAC production [74] Question: Updates on alternative applications for Corbin wet cake? - Management reported progress in testing asphalt emulsion blending, but significant revenues from this application are not expected in 2026 [92]

Financial Data and Key Metrics Changes - Revenue for the full year 2025 reached approximately $120 million, reflecting a 10% year-over-year increase, driven by solid improvements in average selling price and volumes [51][57] - Adjusted EBITDA for 2025 was $13.2 million, representing a 26% improvement compared to 2024, despite the impact of GAC startup costs [52][56] - Gross margin for the year was 27.9%, negatively impacted by GAC ramp-up costs [51] Business Line Data and Key Metrics Changes - The PAC business delivered exceptional performance in 2025, with revenues reaching approximately $120 million, up 10% year-over-year [38][51] - The company is pausing GAC production to conduct a comprehensive engineering and production process optimization review, with no GAC production expected in 2026 [9][60] - The PAC business is expected to generate adjusted EBITDA of $17 million to $20 million for 2026, based on proven operations [61][58] Market Data and Key Metrics Changes - The GAC market fundamentals remain strong, with persistent supply shortages against steady annual growth from existing demand drivers [27][28] - The company has 96% contract visibility on 2026 targeted volumes and 75% visibility through 2027, indicating strong demand and customer loyalty [44][102] Company Strategy and Development Direction - The company is focused on optimizing its GAC production process and has made strategic changes to its leadership team to enhance operational efficiency [32][36] - The decision to pause GAC production is a disciplined capital allocation decision, not a reflection of lost confidence in the market opportunity [60] - The company aims to transition to purchasing domestic bituminous coal feedstock to eliminate moisture-related production constraints and improve yield [17][19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term demand for GAC, citing a significant demand-supply imbalance that is expected to persist [70][108] - The company is committed to rebuilding investor confidence through consistent execution and delivering on its 2026 PAC guidance [61][62] Other Important Information - The company is taking a $45 million write-down on its Corbin assets as part of its decision to switch GAC feedstock [29][30] - The company ended the year with total cash of $15 million, with total debt of $28.5 million, reflecting increased utilization of its credit facility [56] Q&A Session Summary Question: Is there anything that would prevent the company from pursuing GAC? - Management confirmed there are no barriers to pursuing GAC due to strong market fundamentals and expected demand [69][70] Question: Any commentary on regulatory undercurrents affecting PAC? - Management stated there is no regulatory uncertainty affecting the PAC business, and existing regulations remain intact [72] Question: Guidance for free cash flow and balance sheet considerations? - Management indicated that the PAC business is expected to generate free cash flow, with maintenance CapEx included in the guidance [73] Question: Capacity to supply the market if demand increases? - Management confirmed there is capacity to expand PAC production to meet increased demand without cannibalizing GAC production [74] Question: Updates on alternative applications for Corbin wet cake? - Management provided updates on asphalt emulsion testing and other potential applications, noting progress but cautioning against expecting significant revenues in 2026 [92]

Financial Data and Key Metrics Changes - Q4 revenue reached $48.5 million, a 10.6% increase year-over-year, with an operating loss of $10.6 million resulting in a loss of $0.45 EPS [5][7] - Full year revenue for 2025 was $191.2 million, with over $30 million from new products, marking a 16.2% year-over-year growth, leading to a full year operating loss of $5.9 million and a loss of $0.35 EPS [5][6] - Consolidated gross profit was $12.1 million, up 13.7% from the previous year, with a gross margin of 24.9%, a 70 basis point improvement [9][10] Business Line Data and Key Metrics Changes - Battery and energy product segment revenues were $45.9 million, a 15.1% increase year-over-year, with organic growth driven by a 39.6% increase in medical and a 20.4% increase in industrial and other commercial sectors [7][8] - Communications Systems segment revenues declined to $2.6 million, a 35.2% decrease from the previous year, primarily due to delayed orders [8][9] Market Data and Key Metrics Changes - The sales split for the battery business was 73% commercial and 27% government defense, compared to 70% and 30% respectively in the previous year [8] - The backlog at the end of Q4 was $110.2 million, a 22.1% increase from the previous quarter, representing 58% of trailing twelve months sales [9][10] Company Strategy and Development Direction - The company aims to improve the profitability of its Communications Systems business and enhance gross margins in the battery and energy segment [16][17] - Strategic initiatives include transitioning to a unified brand, consolidating operations, and focusing on vertical integration opportunities following the acquisition of Electrochem [18][19] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the growth potential in 2026, citing a healthy backlog and several new product launches [6][25] - The company is targeting organic growth rates of at least double GDP and aims for EBITDA margins greater than 10% in the short term [27][28] Other Important Information - The company completed its ERP transition and operational initiatives to reduce costs during 2025 [5][6] - The transition of various sub-brands to the Ultralife master brand is expected to streamline operations and reduce costs [19][25] Q&A Session Summary Question: Growth and Margin Expansion Goals - Management indicated a roadmap to achieve organic growth and aims for a minimum of 2x GDP growth, targeting over 10% EBITDA margins in the short term [27] Question: Baseline Revenue for Communications Systems - Baseline revenue for the Communications Systems business is defined as $25 million, with potential for larger orders in the future [29] Question: Medical Order Ramp-Up - A new medical order is expected to generate a six-figure revenue stream annually, with initial product launches beginning soon [30][31]

Financial Data and Key Metrics Changes - In 2025, the company achieved record revenue of $66.6 million, a nearly 20% increase over 2024, with testing volume up over 11% and trailing 12-month ASP up over 7% [21][27][29] - Gross margin for 2025 was just over 58%, down from about 60% in 2024, reflecting ASP pressure experienced in the second half of the year [23][24] - Operating expenses for 2025 were $53 million, up about 13% compared to 2024, indicating early signs of scale in the business as revenue growth outpaced expense growth [24][25] Business Line Data and Key Metrics Changes - The company reset the volume run rate from approximately 30,000 tests in Q1 to over 35,000 tests in subsequent quarters, marking the highest Q4 testing volume in Exagen's history [11][21] - ASP at the end of 2025 was approximately $441, up from $411 at the start of the year, driven by new product enhancements and improved revenue cycle management [12][22] Market Data and Key Metrics Changes - The company expanded its sales force from 40 to 45 territories in 2025, with expectations for improved productivity from new sales representatives over time [12][21] - The Pharma Services segment generated $1.7 million in revenue in 2025, significantly up from roughly $100,000 in 2024, with a backlog value of over $4 million expected to be realized over the next 2-3 years [23] Company Strategy and Development Direction - The company aims to own the entire autoimmune diagnostics space, focusing on comprehensive care and innovation to address significant unmet needs in the market [6][18] - The strategy includes advancing adoption through an upgraded sales force, expanding ASP through revenue cycle optimizations, and driving innovation with a structured product cadence [19][20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to achieve sustainable, profitable growth, with revenue expectations for 2026 set between $70 million to $73 million [18][27] - The company is focused on creating a foundation for innovation and evaluating select inorganic opportunities to support long-term growth [19][20] Other Important Information - The company has five promising assets in development and plans to launch one product each year to expand its addressable market opportunity [15][16] - The American College of Rheumatology has begun advocating for the company's products, which is expected to drive medical policy progress with payers [14][50] Q&A Session Summary Question: Why is it the right time to make investments despite profitability targets? - Management indicated that investments in the commercial organization and R&D are necessary for durable cash flow positivity, emphasizing the importance of achieving sustainable growth [32][35] Question: What is the commercialization target for the myositis product? - The company aims to have the myositis offering ready for the clinic by 2027, with ongoing internal feasibility studies and validation of assays [36][37] Question: What is the expected ASP for Q4 2026? - Management did not disclose specific ASP figures but indicated that they expect stabilization and incremental gains in the second half of 2026 [39][40] Question: How is the Northwell Health situation affecting volume growth? - Management views the Northwell situation as a one-time setback and has seen growth initiatives compensate for any lost volume [40][41] Question: What is the status of the local coverage determination for rheumatologic disease? - The company maintains regular contact with the team at MolDX regarding the draft LCD, which is expected to cover broader testing in rheumatologic conditions [76][77] Question: What are medical directors asking about during discussions? - Medical directors are interested in understanding the clinical impact of the company's tests on patient outcomes and are looking for contemporary data to support their decisions [80][81]

Financial Data and Key Metrics Changes - ZYNLONTA net product revenues in Q4 2025 were $22.3 million, up from $16.4 million in Q4 2024, with full-year revenues at $73.6 million compared to $69.3 million in 2024 [21][22] - Total operating expenses were $41 million for Q4 2025 and $202.9 million for the full year, with adjusted operating expenses down 15% for Q4 and 6% for the full year compared to the previous year [21][22] - The net loss for Q4 2025 was $6.4 million, significantly reduced from a net loss of $30.7 million in Q4 2024, while the full-year net loss was $142.6 million compared to $157.8 million in 2024 [22][23] Business Line Data and Key Metrics Changes - The company focused on ZYNLONTA, optimizing lifecycle management and advancing clinical trials such as LOTIS-5 and LOTIS-7, which are expected to drive future growth [5][6] - The performance in Q4 was strong, driven by variability in customer ordering patterns and activation of new accounts, indicating a positive trend in sales [8] Market Data and Key Metrics Changes - The company anticipates a peak annual U.S. revenue opportunity for ZYNLONTA of $600 million to $1 billion, contingent on regulatory approval and compendia inclusion [7][11] - The treatment landscape for DLBCL is evolving, with a current 60/40 split between complex therapies and broadly accessible therapies, indicating a competitive market environment [15] Company Strategy and Development Direction - The strategic plan focuses on establishing ZYNLONTA as a backbone therapy in DLBCL, with significant patient benefits expected in indolent lymphomas [6][11] - The company aims to maintain a strong market position despite increased competition from bispecific therapies, leveraging its differentiated clinical profile [5][15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving key milestones in 2026, including top-line data for LOTIS-5 and further data for LOTIS-7, which are critical for future growth [25][26] - The company believes it has laid a solid foundation for long-term growth, with a strengthened balance sheet and a cash runway extending into 2028 [10][24] Other Important Information - The company has made significant progress in reducing operating costs by approximately 50% while enhancing its leadership and talent across the organization [5][6] - An amendment to the royalty purchase agreement with HealthCare Royalty has provided greater strategic flexibility for the company [10] Q&A Session Summary Question: How are PFS events tracking for LOTIS-5? - Management is confident in the Q2 timing for the top-line readout and will share primary and secondary endpoints at that time [29][30] Question: Is the $200-$300 million opportunity for LOTIS-5 conservative? - Management believes the profile seen in the safety run-in supports a meaningful role in the second-line DLBCL market, with potential for higher peak sales depending on clinical outcomes [34][35] Question: What is the expected R&D spend moving forward? - R&D expenses are expected to decrease in 2026 and 2027, assuming the current number of trials remains stable [42][44] Question: How should capital allocation priorities be viewed? - The company is focused on driving ZYNLONTA growth and has allocated capital for ongoing trials and pre-launch activities, with strategic flexibility provided by the amended royalty agreement [48][50] Question: What is the current commercial run rate for ZYNLONTA? - The company has maintained its market share despite increased competition, with expectations for significant sales growth following LOTIS-5 approval [58][59]

Financial Data and Key Metrics Changes - In Q2 fiscal 2026, the company's sales were nearly $8 billion, reflecting a decline of 2.6% year-over-year, impacted by nearly 500 basis points from optimization actions [14][15] - Adjusted EBITDA grew by 23% to $179 million, with an Adjusted EPS of $0.62, significantly up from $0.22 in the previous year [18][24] - Free cash flow increased by $50 million to $243 million, contributing to a reduction in net debt to its lowest level since fiscal 2018, with a net leverage ratio of 2.7 times [20][21] Business Line Data and Key Metrics Changes - Natural product sales grew by 7%, outperforming the market, while conventional product sales declined by 12%, primarily due to network optimization efforts [15][16] - Retail sales fell by 8%, attributed to strategic store closures, although same-store sales improved sequentially by 100 basis points [16] Market Data and Key Metrics Changes - The company targets a $90 billion addressable market, with expectations for low single-digit average sales growth from fiscal 2026 through fiscal 2028 [11][24] - The overall business outperformed the market, with sales growth in line with the target addressable market's estimated low double- to single-digit growth rate [10][15] Company Strategy and Development Direction - The company is focused on a value creation strategy aimed at achieving profitable growth with customers and suppliers, enhancing capabilities in areas such as supply chain, technology, and private brands [5][12] - The implementation of an AI-powered supply chain planning platform, Relex, is expected to improve customer service and inventory management [7][8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in returning to growth in fiscal 2027, driven by a strong new business pipeline and the cycling of larger optimization actions [10][24] - The company remains focused on helping retailers differentiate themselves in a dynamic market, emphasizing the importance of natural and organic products [11][62] Other Important Information - The company repurchased nearly 750,000 shares for approximately $25 million, reflecting confidence in long-term value creation [22] - An updated outlook for full-year sales is now projected at $31 billion to $31.4 billion, a reduction of 1.9% at the midpoint [23] Q&A Session Summary Question: Impact of network optimization on conventional sales - The company noted a 500 basis point headwind from network optimization, primarily due to the exit from the Allentown facility, which was executed faster than anticipated [30] Question: Underlying business trends in conventional sales - Excluding network optimization impacts, the underlying business showed low single-digit growth, driven by inflation and volume trends [33] Question: Composition of the new business pipeline - The majority of the pipeline consists of incremental categories with existing customers, reflecting healthy relationships and growth opportunities [38] Question: Future of productivity gains - Productivity increased by 6%, driven by automation and lean practices, with expectations for continued improvements [41] Question: Impact of SNAP changes on guidance - The company believes the impact of SNAP changes is manageable and has been factored into the guidance for the remainder of the year [51] Question: Vendor-funded promotions and inflation outlook - Vendor promotions have become more selective, with a focus on peak holiday moments, while inflation is modeled at low single digits for the remainder of the year [67]

Financial Data and Key Metrics Changes - Stagwell reported a 6% growth in 2025, driven by a 13% increase in digital transformation and a 6% increase in marketing services [3] - Adjusted EBITDA for 2025 was $422 million, with a margin of 17.4%, and excluding advocacy, it increased 15.9% to $377 million [9][22] - Free cash flow more than doubled to $187 million, representing nearly 45% conversion of Adjusted EBITDA [25] Business Line Data and Key Metrics Changes - The Marketing Cloud segment exceeded $105 million in revenue, growing 34% organically for the full year, with 41% organic growth in Q4 [6] - Digital transformation and marketing services showed organic growth of 9% and 5% respectively [4] - The marketing cloud grew 230% or 34.3% organically, reflecting increased adoption of its product suite [20] Market Data and Key Metrics Changes - The company expects approximately 10% net revenue growth in 2026, primarily organic, driven by political increases and new business [4] - The media segment is anticipated to return to high single-digit organic growth, supported by new media technology products [8] - The company is entering a political super cycle with over $20 billion expected to be invested in politics [5] Company Strategy and Development Direction - Stagwell is focusing on accelerated organic growth, market share expansion, and advanced AI applications [3] - The company has slowed down planned acquisitions to pivot towards AI application development [5] - A significant buyback program has been announced, reflecting confidence in the company's growth and valuation [17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in strong double-digit growth for digital transformation in 2026, driven by increased AI investments [30] - The company anticipates a strong political season, contributing positively to advocacy revenue [36] - Management highlighted the importance of premium creative services, which remain in high demand despite industry disruptions [35] Other Important Information - The company has made significant efficiency gains, with adjusted EBITDA margins improving and a focus on technology-led operational changes [24] - The Marketing Cloud generated a positive margin for the first time in Q4, reaching an Adjusted EBITDA margin of 10.8% [26] - The company has repurchased approximately 55 million shares over the past four years, reflecting a commitment to returning capital to shareholders [27] Q&A Session Summary Question: What is the confidence in the continuation of digital transformation growth? - Management expects even stronger double-digit growth in digital transformation for 2026 due to increased AI investments and a realigned business model [30] Question: What revenue growth and EBITDA contribution are expected from The Machine and Marketing Cloud? - Management anticipates significant interest and potential revenue growth from these products, aiming for at least $25 million in the first year [33] Question: How is creative pacing given AI disruption concerns? - Management noted that premium creative remains in high demand, with agencies achieving record revenues [35] Question: What are the early trends for advocacy in 2026? - Early trends indicate a strong political season ahead, with significant expenditures expected in the upcoming midterm cycle [36] Question: What is the potential for incremental cost-cutting and efficiencies? - Management is on track to achieve $80 million-$100 million in cost actions, with additional potential upside identified [39] Question: What drove the doubling of free cash flow in 2025? - Focus on cash flow management, faster billing, and improved collection processes contributed to the doubling of free cash flow [42]